Semaglutide shows preliminary evidence of improved liver biomarkers in obese adolescents with prediabetes/T2D and MASLD

Adolescent obesity and associated metabolic complications like Type 2 Diabetes (T2D) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) are rapidly increasing, posing significant long-term health risks. Current treatments often fall short in comprehensively addressing both glycemic control and hepatic steatosis in this vulnerable population. Glucagon-like peptide-1 (GLP-1) plays a crucial role in glucose homeostasis and has shown promise in adult MASLD, but its specific effects on delaying β-cell function loss and reducing liver fat in obese youth with early T2D or prediabetes remain an important area of investigation.

This investigation was conducted as a case series to explore the effects of semaglutide in obese youth. The study population included adolescents diagnosed with prediabetes or new onset Type 2 Diabetes who also presented with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The abstract does not specify the exact number of participants (n), the precise dosage or route of semaglutide administration, the treatment frequency, or the duration of the intervention. The primary focus was to assess changes in liver biomarkers, although specific assay methods (e.g., ELISA, liver biopsy) were not detailed in the abstract.

Preliminary evidence indicated that semaglutide treatment was associated with improvements in liver biomarkers among the obese adolescents. The study aimed to understand the role of GLP-1 in the pathogenesis of T2D in youth and to explore its potential salutary effects. Specifically, researchers observed that semaglutide showed an ability to delay the progressive loss of β-cell function and reduce hepatic steatosis in the studied cohort. While the abstract highlights these positive observations, it does not provide specific quantitative data such as exact percentages of improvement, p-values, or fold-changes for the observed biomarker changes. The findings suggest a beneficial impact on both glycemic control-related parameters and liver health. > Semaglutide treatment in obese youth with prediabetes/new onset T2D and MASLD was associated with preliminary evidence of improved liver biomarkers, indicating potential to delay β-cell function loss and reduce hepatic steatosis.